Ascendis Pharmac

Forecast & Rating20 analysts currently cover Ascendis Pharmac, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $306.94, about 34.7% upside from the current price of $227.87. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 60.2% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Ascendis Pharmac closely still see room for the stock to rise. Data as of Oct 3, 2026; for reference only and not investment advice.